Last updated: October 21, 2026

Renacidin is a legacy urinary irrigation product containing citric acid, gluconolactone, and magnesium carbonate. Its market is narrow, institutional, and procedure-driven. Public sources do not report Renacidin-specific revenue, unit sales, operating margins, or valuation. The commercial outlook therefore depends on product availability, urology utilization, hospital purchasing, regulatory continuity, and substitution by mechanical stone removal or alternative irrigation approaches rather than conventional branded-pharmaceutical growth.

What is Renacidin and what is it used for?

Renacidin is a sterile irrigation solution used in urology. Its labeled uses include dissolution of certain bladder calculi and prevention of encrustations on urinary catheters and cystostomy tubes. The product is not an oral drug and does not compete in the conventional prescription-drug market.

The formulation contains:

Component	Role in the product
Citric acid	Acidifying and chelating component
Gluconolactone	Buffering and formulation component
Magnesium carbonate	Magnesium source and buffering component

Renacidin is administered through urinary drainage or irrigation systems under clinical supervision. The product is associated with catheter maintenance and selected stone-management protocols rather than chronic outpatient drug therapy. Its prescribing information requires careful monitoring because improper use can result in infection, electrolyte abnormalities, renal complications, or systemic toxicity (DailyMed, n.d.).

What is the FDA regulatory status of Renacidin?

Renacidin is an FDA-approved urinary irrigation solution associated with Mission Pharmacal Company. Public FDA and labeling records identify the product as an approved prescription irrigation product rather than a recently approved new molecular entity.

Regulatory item	Publicly reported position
Product	Renacidin Irrigation
Active ingredients	Citric acid, gluconolactone, magnesium carbonate
Dosage form	Sterile irrigation solution
Therapeutic area	Urology; urinary calculi and catheter encrustation
FDA pathway	Legacy approved drug application
Current sponsor or marketer	Mission Pharmacal Company is identified in current product materials
FDA exclusivity	No meaningful current NCE, orphan, pediatric, or other modern exclusivity period is publicly associated with the product
Regulatory risk	Label compliance, manufacturing continuity, sterile-product quality, and safety monitoring

Renacidin’s commercial value does not arise from regulatory exclusivity. Its position depends on the continued availability of an approved product for a specialized clinical use.

What is the Orange Book status of Renacidin?

The Orange Book is the relevant source for FDA-listed patents, exclusivity, therapeutic equivalence, and approved drug application information. Renacidin is a legacy product, and public FDA data do not indicate a current commercially material patent or exclusivity barrier protecting its active-ingredient combination.

The practical implications are:

No modern composition-of-matter patent protects the formulation.
No remaining NCE exclusivity period restricts competing development.
A competitor could pursue an approved product or an alternative regulatory pathway, subject to FDA requirements.
The principal barriers are likely manufacturing, sterile filling, validation, distribution, and limited market size.

The absence of active Orange Book protection does not guarantee rapid generic entry. A small market can deter development even when the legal patent barrier is limited.

What patents protect Renacidin?

No current patent estate appears to provide material exclusivity for Renacidin’s active ingredients or core clinical uses. The formulation is based on long-established chemical ingredients, and any original product patents would have expired decades ago.

Composition patents

Citric acid, gluconolactone, and magnesium carbonate are established compounds. A new composition-of-matter patent is not a realistic source of current exclusivity for the marketed product.

Formulation patents

A formulation patent could theoretically cover concentration, pH, sterility, packaging, container closure, or stability characteristics. Publicly available product information does not identify a current formulation patent that materially blocks competition with Renacidin.

Method-of-use patents

The labeled uses involve urinary stone dissolution and prevention of catheter encrustation. These uses are old and unlikely to support a current enforceable exclusivity position without a narrowly defined, later-developed clinical protocol.

Manufacturing patents

The most commercially relevant intellectual property may relate to sterile manufacturing processes, quality systems, packaging, or supply-chain know-how. Such protection would be difficult to assess from public patent records and would not necessarily prevent a qualified competitor from developing a comparable product.

When does Renacidin lose exclusivity?

Renacidin does not have a meaningful future loss-of-exclusivity event comparable to a major branded drug. Its principal patent and regulatory exclusivity periods expired long ago. The relevant commercial question is whether an alternative manufacturer enters the market, not whether a high-value patent cliff occurs.

Exclusivity category	Renacidin position
Composition-of-matter patent	Expired or not commercially relevant
Formulation patent	No material current protection identified
Method-of-use patent	No material current protection identified
NCE exclusivity	Expired
Orphan-drug exclusivity	Not identified
Pediatric exclusivity	Not identified
Current patent cliff	None
Primary competitive risk	Product substitution or new entrant

How strong is the Renacidin patent estate?

The Renacidin patent estate is weak as a conventional pharmaceutical exclusivity platform. Its commercial defensibility is better characterized as an operational niche.

Patent-strength assessment

Factor	Assessment
Composition protection	Low
Formulation protection	Low based on public information
Method-of-use protection	Low
Manufacturing know-how	Potentially moderate, but not publicly quantifiable
Regulatory switching cost	Moderate because sterile irrigation products require quality compliance
Prescriber switching cost	Low to moderate
Supply scarcity value	Potentially high during shortages
Generic-entry deterrence	Market size is a larger deterrent than patents

A small approved product can remain commercially durable despite weak patents when physicians know the product, hospitals have established protocols, and competing suppliers do not view the market as large enough to justify development costs.

What market dynamics affect Renacidin?

Renacidin operates in a concentrated specialty market. Demand is tied to urologists, hospitals, catheter-management protocols, and treatment of selected urinary stones. It is not driven by broad consumer advertising or large primary-care prescribing.

Demand drivers

Demand can arise from:

Use in selected bladder-stone management protocols
Prevention or treatment of catheter and cystostomy-tube encrustation
Hospital and urology-clinic procedure volumes
Patients with recurrent encrustation or complex urinary drainage
Limited availability of comparable approved irrigation products

Demand constraints

The market is constrained by:

Low disease and procedure volume relative to major pharmaceutical categories
Availability of endoscopic, laser, shock-wave, or mechanical stone-removal procedures
Clinical caution associated with irrigation-related adverse events
Dependence on specialist prescribing
Hospital formulary controls
Potential substitution with catheter exchange, mechanical flushing, or other irrigation approaches
Lack of strong patent protection

Renacidin is therefore a low-volume specialty product rather than a growth pharmaceutical.

What safety issues affect the commercial outlook?

Safety concerns have influenced the product’s market position. The FDA has historically communicated concerns regarding improper use of Renacidin, including continuous upper-tract irrigation and inadequate monitoring. Reported risks include serious urinary tract infection, sepsis, hypermagnesemia, renal dysfunction, and other complications when the product is used outside labeled conditions or without appropriate clinical supervision (U.S. Food and Drug Administration, 2009).

These risks have several commercial consequences:

Hospitals may restrict use to specialized urology services.
Prescribers may prefer procedural alternatives.
Training and protocol requirements increase institutional friction.
Product demand may be concentrated in experienced centers.
Any manufacturing or labeling event could have an outsized effect because the market has limited redundancy.

Safety risk is not equivalent to product withdrawal. The commercial issue is the balance between a narrow clinical benefit and the monitoring burden required for appropriate use.

Which companies are challenging Renacidin?

No major, publicly visible Paragraph IV campaign appears to target Renacidin as a high-value branded product. The absence of litigation is consistent with the product’s age and limited revenue opportunity.

Potential competition is more likely to emerge from:

A generic or equivalent sterile irrigation manufacturer
Hospital-compounded citrate-based solutions, where legally and clinically appropriate
Alternative catheter-encrustation products
Mechanical catheter exchange and irrigation protocols
Endoscopic stone-removal technologies
Other approved urinary irrigation products

Paragraph IV risk

A Paragraph IV challenge is unlikely to be the principal competitive mechanism. The product’s limited sales potential reduces the incentive to fund a conventional abbreviated new drug application campaign and subsequent patent litigation, particularly when public records do not show a meaningful active patent barrier.

A competitor could instead pursue a non-infringing formulation, a different approved indication, or a drug-development strategy based on clinical and manufacturing differentiation.

What patent litigation affects Renacidin?

No prominent current patent litigation involving Renacidin is publicly associated with the product. There is no clear indication of an active dispute involving:

Orange Book-listed patents
Paragraph IV certifications
ANDA litigation
Formulation patent infringement
Method-of-use patent enforcement
Settlement agreements delaying generic entry

The litigation profile is materially different from large urology drugs such as overactive-bladder therapies, prostate drugs, or oncology products. Renacidin’s key legal exposure is more likely to involve product liability, manufacturing quality, labeling, or supply obligations than patent enforcement.

What is the financial trajectory for Renacidin?

Renacidin-specific financial data are not publicly disclosed. Mission Pharmacal is a private company, and public filings do not provide a separate Renacidin revenue line, gross margin, EBITDA contribution, or geographic sales breakdown.

Financial profile

Financial metric	Public position
Annual Renacidin revenue	Not publicly reported
Unit volume	Not publicly reported
Average selling price	Not publicly reported
Gross margin	Not publicly reported
Net sales growth	Not publicly reported
Product-level operating profit	Not publicly reported
Company allocation	Not separately disclosed
Revenue concentration	Likely high because of niche-product status
Growth profile	Likely mature and volume-limited

The product may produce attractive contribution margins if manufacturing costs are controlled and supply remains reliable. That does not imply large absolute profit. A low-volume sterile product can have favorable pricing but still generate modest total revenue.

Likely trajectory

Renacidin’s financial trajectory is best characterized as:

Mature rather than expansionary
Dependent on recurring institutional demand
Sensitive to supply interruptions
Exposed to substitution by procedures and catheter-management practices
Unlikely to generate major revenue growth without a new indication, expanded distribution, or market shortage
Potentially valuable as part of a broader specialty portfolio

Price increases could raise nominal revenue, but sustained growth would depend on maintaining access and avoiding clinical substitution. Because the product has no obvious exclusivity moat, price increases could also encourage alternative sourcing or institutional protocol changes.

How does Renacidin compare with competing treatment options?

Renacidin competes against treatment pathways more than against a single branded drug.

Option	Primary use	Commercial relationship to Renacidin
Renacidin	Selected urinary stone dissolution and catheter-encrustation management	Approved niche irrigation product
Mechanical catheter exchange	Encrustation management	Direct procedural substitute
Endoscopic stone removal	Bladder or urinary stone treatment	Substitute for dissolution in suitable patients
Laser lithotripsy	Stone fragmentation	Procedural substitute
Shock-wave lithotripsy	Selected urinary stones	Alternative treatment pathway
Hospital-compounded irrigation	Institution-specific use	Potential formulation substitute
Other urinary irrigation products	Catheter maintenance or urologic irrigation	Potential product substitute

Renacidin’s advantage is its established labeling and availability as a finished sterile product. Its disadvantage is that many competing approaches are procedural and may offer faster or more controllable intervention for selected patients.

What generic launch risks exist for Renacidin?

A generic launch would face limited patent risk but meaningful execution risk.

Barriers to entry

Small addressable market
Sterile manufacturing requirements
Need for validated formulation and container-closure systems
Limited commercial return on regulatory investment
Hospital procurement concentration
Need to establish urology-specialist adoption
Potentially difficult historical safety profile
Uncertain reimbursement and purchasing economics

Generic launch scenarios

Scenario	Commercial effect
No entrant	Renacidin retains niche demand and supply value
One approved competitor	Price pressure and hospital dual sourcing
Multiple competitors	Lower pricing, reduced share, possible formulary substitution
Supply disruption	Temporary price and demand volatility
Label or safety restriction	Rapid contraction in use
New clinical evidence supporting use	Moderate demand expansion

The most credible competitive threat is a single specialized entrant seeking supply reliability or hospital-contract access rather than a large generic manufacturer pursuing mass-market volume.

What is the geographic coverage of Renacidin?

Renacidin’s public commercial visibility is strongest in the United States. International availability, registrations, distributors, and product names are not consistently disclosed in public materials. Geographic expansion is constrained by the product’s niche indication, local sterile-drug requirements, and the need for country-specific regulatory approval.

A broader international strategy would require:

National product registrations
Local pharmacovigilance infrastructure
Urology-distributor partnerships
Sterile supply-chain capacity
Reimbursement and hospital procurement access
Country-specific labeling and safety review

International expansion could increase market size, but it would also raise regulatory and distribution costs. The product’s narrow clinical use limits the economic appeal of broad geographic commercialization.

What manufacturing and IP barriers affect Renacidin?

The principal barriers are operational rather than intellectual property-based.

Manufacturing barriers

Renacidin requires:

Validated sterile production
Reliable sourcing of pharmaceutical-grade ingredients
Controlled pH and formulation characteristics
Container-closure integrity
Stability testing
Microbiological quality control
Lot-release testing
Regulatory-compliant labeling and distribution

Any shortage of sterile manufacturing capacity can materially affect availability. The product’s niche volume may also make dedicated production inefficient, increasing dependence on contract or shared facilities.

IP barriers

Publicly visible IP barriers appear limited. A competitor would more likely need to overcome formulation development, quality-control, FDA review, procurement access, and physician adoption than a blocking patent.

Key Takeaways

Renacidin is a legacy sterile urinary irrigation product containing citric acid, gluconolactone, and magnesium carbonate.
Its market is narrow and specialist-driven, with demand tied to urinary stone management and catheter encrustation.
No material current patent or regulatory exclusivity barrier is publicly evident.
Renacidin-specific revenue, margins, volume, and growth data are not publicly disclosed.
The product’s financial value depends on recurring niche demand, manufacturing reliability, and limited competitive supply.
Generic entry is legally feasible but commercially difficult because the market is small and sterile manufacturing is complex.
Procedural stone removal, catheter exchange, and alternative irrigation practices are important substitutes.
Safety monitoring and appropriate-use restrictions limit broad adoption.
The main business risk is not a patent cliff. It is substitution, supply disruption, regulatory action, or entry by a qualified sterile-product competitor.

Frequently Asked Questions

Is Renacidin still FDA approved?

Public FDA labeling records identify Renacidin as an approved urinary irrigation product marketed by Mission Pharmacal Company.

Is Renacidin a generic drug?

Renacidin is a branded legacy product. Its active ingredients are established compounds, but public records do not indicate a commercially significant generic-equivalence market comparable to major oral drugs.

Does Renacidin have active patents?

No material active patent protection for the core formulation or labeled uses is publicly evident. Its commercial position is based primarily on product availability, manufacturing capability, and clinical familiarity.

Can Renacidin be used for kidney stones?

Its labeled uses concern selected urinary calculi and urinary-tract irrigation. Use in the upper urinary tract carries important safety considerations and must follow current prescribing information and specialist protocols.

Is Renacidin revenue publicly reported?

No separate Renacidin revenue or profit disclosure is publicly available. Mission Pharmacal does not provide a public product-level financial breakdown for the drug.

References

DailyMed. (n.d.). Renacidin irrigation solution: Citric acid, gluconolactone, and magnesium carbonate prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (2009). Renacidin irrigation solution: Risk of serious adverse events with inappropriate use. FDA Drug Safety Communication. https://www.fda.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
Mission Pharmacal Company. (n.d.). Renacidin irrigation solution product information. https://www.missionpharmacal.com/

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for RENACIDIN
What excipients (inactive ingredients) are in RENACIDIN?	RENACIDIN excipients list
DailyMed Link:	RENACIDIN at DailyMed

Drug Class	Anti-coagulant Calculi Dissolution Agent
Mechanism of Action	Acidifying Activity Calcium Chelating Activity Irrigation
Physiological Effect	Decreased Coagulation Factor Activity

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
United Guardian	RENACIDIN	citric acid; gluconolactone; magnesium carbonate	SOLUTION;IRRIGATION	019481-001	Oct 2, 1990		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for RENACIDIN

Pharmacology for RENACIDIN